Tekmira Pharmaceuticals Corporation Strengthens Development Team With Appointment of Dr. Mark Kowalski as Chief Medical Officer
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
VANCOUVER, British Columbia, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that Dr. Mark Kowalski, M.D., Ph.D. has joined its team as Chief Medical Officer and Senior Vice President.
Help employers find you! Check out all the jobs and post your resume.
VANCOUVER, British Columbia, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that Dr. Mark Kowalski, M.D., Ph.D. has joined its team as Chief Medical Officer and Senior Vice President.
Help employers find you! Check out all the jobs and post your resume.